Eli Lilly
NICE recommends two new treatments for inflammatory arthritis
June 18, 2021Medical Communications Eli Lilly, NICE, Novartis
NICE has recommended two new treatments for axial spondyloarthritis, an underdiagnosed and debilitating type of inflammatory arthritis. Ixekizumab (also known …
Eli Lilly and MiNA Therapeutics to collaborate on saRNA research
May 12, 2021Research and Development Eli Lilly
Eli Lilly and MiNA Therapeutics have announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small …
Eli Lilly to collaborate with diabetes tech companies on insulin pen
May 10, 2021Sales and Marketing Eli Lilly, diabetes
Eli Lilly has signed strategic international agreements with four companies – Dexcom, Glooko, myDiabby Healthcare, and Roche – with the …
Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
April 19, 2021Sales and Marketing COVID-19, Eli Lilly, FDA, covid-19 treatment, lilly, pharma, pharma news
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the treatment of COVID-19, per the …
Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
March 17, 2021Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …
Eli Lilly’s COVID-19 treatment combination 87% effective in Phase III trial
March 11, 2021COVID-19, Eli Lilly, covid-19 treatment
Eli Lilly has shown positive results in its Phase III combination drug trial, which reduced hospitalisations and deaths related to …
Lilly’s cancer drug Retsevmo gets UK approval for multiple indications
March 10, 2021Research and Development Cancer, Eli Lilly, MHRA
The MHRA has granted conditional marketing authorisation for Eli Lilly’s Retsevmo (selpercatinib) as monotherapy for a number of cancer indications.
CHMP recommends Lilly’s bamlanivimab for COVID-19 patients
March 8, 2021Sales and Marketing COVID-19, EMA, Eli Lilly
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly’s bamlanivimab …
Eli Lilly’s diabetes drug tirzepatide reduces blood glucose and weight in Phase III trials
February 18, 2021Eli Lilly, diabetes
Eli Lilly’s tirzepatide led to significant haemoglobin A1C (HbA1C) and body weight reductions from baseline in adults with type 2 …
University of Glasgow and Lilly sign £4.6m immunological disease partnership
February 15, 2021Sales and Marketing Eli Lilly, University of Glasgow, arthritis, fibrosis, lilly, uofg
The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 …
FDA grants emergency authorisation to Lilly’s COVID-19 antibody combination
February 11, 2021COVID-19, Eli Lilly
The FDA has granted emergency use authorisation for Eli Lilly’s antibodies bamlanivimab (LY-CoV555) 700mg and etesevimab (LY-CoV016) 1400mg, to be …
Lilly’s antibody could reduce COVID-19 risk by 80%, trial shows
January 22, 2021Medical Communications COVID-19, Eli Lilly
Eli Lilly’s neutralising antibody bamlanivimab significantly reduced the risk of contracting symptomatic coronavirus among residents and staff of long-term care …
Eli Lilly’s Alzheimer’s drug slows clinical decline in Phase II trial
January 11, 2021Sales and Marketing Alzheimer's, Eli Lilly
Eli Lilly’s donanemab has shown significant slowing of decline in a composite measure of cognition and daily function in patients …
Eli Lilly scoops up gene therapy specialist Prevail Therapeutics for a potential $1.04bn
December 16, 2020Research and Development, Sales and Marketing Eli Lilly, Prevail, acquisition
Eli Lilly has struck a deal to acquire Prevail Therapeutics in a transaction that could be valued at up to …
Lilly’s tirzepatide generates significant reductions in weight and blood sugar in type 2 diabetes patients
December 10, 2020Research and Development Eli Lilly, diabetes, tirzepatide
Eli Lilly has announced new data for its glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide, showing …
